Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

BACKGROUND: The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0 mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in subjects with type 2 diabetes (T2D) and high CV risk. The effects of gender, age and baseline CV risk on outcomes are importa...

Descripción completa

Detalles Bibliográficos
Autores principales: Leiter, Lawrence A., Bain, Stephen C., Hramiak, Irene, Jódar, Esteban, Madsbad, Sten, Gondolf, Theis, Hansen, Thomas, Holst, Ingrid, Lingvay, Ildiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551895/
https://www.ncbi.nlm.nih.gov/pubmed/31167654
http://dx.doi.org/10.1186/s12933-019-0871-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551895/
https://www.ncbi.nlm.nih.gov/pubmed/31167654
http://dx.doi.org/10.1186/s12933-019-0871-8

Ejemplares similares